Download PDF
Onkologische Welt 2018; 09(04): 154-156
DOI: 10.1055/s-0038-1670910
Dermato-Onkologie: ASCO 2018
Georg Thieme Verlag KG Stuttgart · New York

Aktuelles zur Therapie von Melanom und Merkelzellkarzinom

Hauttumoren auf dem ASCO 2018
Ine Schmale
1   Westerburg
› Author Affiliations
Further Information

Publication History

Publication Date:
10 September 2018 (online)

 
 PDF Download Permissions and Reprints

Zusammenfassung

Immunonkologische Checkpoint-Inhibitoren und BRAF/MEK-Inhibitoren sind beim malignen Melanom in der metastasierten Situation etabliert und rücken nun in das adjuvante Setting vor. In der Sitzung zu Hauttumoren wurde auf der Jahresversammlung der American Society of Clinical Oncology (ASCO) die Immuntherapie auch als wirk-same Option beim aggressiven Merkelzellkarzinom in allen Therapielinien bestätigt.


#

 


#

  • Literatur

  • 1 Weber J. et al. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238). ASCO. 2018. Abstract 9502
    Google Scholar
  • 2 Dummer R. et al. Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or ENCO in BRAFmutant melanoma. ASCO. 2018. Abstract 9504
    Google Scholar
  • 3 Topalian SL. et al. Nivolumab as neoadjuvant therapy in patients with resectable Merkel cell carcinoma in CheckMate 358. ASCO. 2018. Abstract 9505
    Google Scholar
  • 4 Nghiem P. et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as firstline therapy. ASCO. 2018. Abstract 9506
    Google Scholar
  • 5 Nghiem P. et al. Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy. ASCO. 2018. Abstract 9507
    Google Scholar

  • Literatur

  • 1 Weber J. et al. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238). ASCO. 2018. Abstract 9502
    Google Scholar
  • 2 Dummer R. et al. Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or ENCO in BRAFmutant melanoma. ASCO. 2018. Abstract 9504
    Google Scholar
  • 3 Topalian SL. et al. Nivolumab as neoadjuvant therapy in patients with resectable Merkel cell carcinoma in CheckMate 358. ASCO. 2018. Abstract 9505
    Google Scholar
  • 4 Nghiem P. et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as firstline therapy. ASCO. 2018. Abstract 9506
    Google Scholar
  • 5 Nghiem P. et al. Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy. ASCO. 2018. Abstract 9507
    Google Scholar

   Permissions and Reprints